The Food and Drug Administration granted accelerated approval to a new breast cancer treatment on Sept. 4, continuing a major stretch of oncology actions by the agency.
The accelerated approval pathway allows the FDA to approve drugs for serious conditions based on a surrogate endpoint reasonably likely to predict clinical benefit, enabling patients to access promising therapies while confirmatory trials continue.
The approval follows recent FDA oncology actions including a first-in-class targeted therapy for metastatic pancreatic cancer on Aug. 26 and a new drug for polycythemia vera on Aug. 28, according to the agency.
Breast cancer is the most common cancer diagnosis among American women, with more than 300,000 new cases projected annually in the United States. Each new approved therapy represents a potential additional treatment option for patients who have exhausted existing regimens.
The specific drug name and the breast cancer subtype it targets were not detailed in the agency’s initial announcement summary.
For the millions of Americans affected by breast cancer, either directly or as caregivers and family members, expanded treatment options can translate to additional months or years of survival, particularly for patients with aggressive or treatment-resistant forms of the disease.
The accelerated approval pathway has been a critical regulatory tool for oncology, allowing cancer drugs to reach patients faster than through the traditional approval process. Manufacturers receiving accelerated approval are required to conduct post-marketing confirmatory trials to verify the drug’s clinical benefit.